None
Quote | Prevail Therapeutics Inc. (NYSE:PRVL)
Last: | $ |
---|---|
Change Percent: | -0.16% |
Open: | $19.09 |
Close: | $18.91 |
High: | $19.25 |
Low: | $18.35 |
Volume: | 103,841 |
Last Trade Date Time: | 02/12/2020 04:42:18 pm |
News | Prevail Therapeutics Inc. (NYSE:PRVL)
Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with ...
Gain Therapeutics has filed to raise $40 million in a U.S. IPO. The firm is a preclinical biopharma developing treatments for lysosomal storage disorders. GANX has a number of research collaborations, but is still at a very early stage of development, so maybe more relevant for in...
Message Board Posts | Prevail Therapeutics Inc. (NYSE:PRVL)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Prevail Therapeutics Inc. Company Name:
PRVL Stock Symbol:
NYSE Market:
NEW YORK, NY / ACCESSWIRE / January 8, 2021 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Altimar Acquisition Corp. (NYSE: ATAC ) relat...
Shares of Eli Lilly (NYSE: LLY) jumped by 6% on Tuesday. The healthy gain came after the drugmaker raised its full-year 2020 revenue and earnings guidance, and provided a positive outlook for 2021. Lilly also announced plans to acquire Prevail Therapeutics (NASDAQ: PRVL) . ...
Eli Lilly (NYSE: LLY) will soon add a new asset to its portfolio. The veteran pharmaceutical company announced on Tuesday that it has signed a definitive agreement to acquire gene therapy specialist Prevail Therapeutics (NASDAQ: PRVL) . The price is $22.50 per share in c...